The initial success of Viagra has left a peculiar shadow over the broader pharmaceutical landscape. While the company initially harvested substantial gains , generic versions now erode its market share , presenting difficulties for investors considering investments in affected companies. Doubts about the sustained viability of ED medication income

The emergence of so-called "Elite Luxury Sildenafil" – often referring to exceptionally high doses administered by rogue physicians – represents a particularly alarming trend. While standard dosages of Viagra are intended for treating erectile dysfunction safely in most patients, these significantly elevated amounts pose a grave risk to circula